Spruce Street Capital LP
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$629.0M2026 Q3
Positions39
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.64.0%
What Changed This Quarter?
Top Holdings
KNSA
Kiniksa Pharmaceuticals
10.9%
LBRX
LB Pharmaceuticals
8.6%
RLAY
Relay Therapeutics
8.6%
ANRO
Alto Neuroscience
6.8%
ALKS
Alkermes
6.1%
ENTX
Entera Bio
5.2%
DNTH
Dianthus Therapeutics
5.0%
SVRA
Savara
4.4%
New / Increased
9 new · 8 increased
ENTXNEW
Entera Bio
5.2%
OBXNEW
Obsidian Therapeutics
2.7%
SGMTNEW
Sagimet Biosciences
2.2%
YARWNEW
Yarrow Bioscience
2.2%
KRSANEW
Korsana Biosciences
1.6%
ZLAB
Zai Lab
4.4%
+273.4%
ALKS
Alkermes
6.1%
+74.4%
SVRA
Savara
4.4%
+55.9%
Reduced / Exited
0 reduced · 0 sold out
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.